Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1524-4741.2007.00456.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the role of circular RNA (circ-FAF1) as a diagnostic biomarker for breast cancer in a cohort of Egyptian breast cancer patients.
Mol Biol Rep
January 2025
Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Background: The identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients.
Methods And Results: This case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects.
Leveraging survival analysis and machine learning for accurate prediction of breast cancer recurrence and metastasis.
Sci Rep
January 2025
Center for Informatics Science (CIS), School of Information Technology and Computer Science, Nile University, 26th of July Corridor, Sheikh Zayed City, Giza, 12588, Egypt.
Breast cancer, with its high incidence and mortality globally, necessitates early prediction of local and distant recurrence to improve treatment outcomes. This study develops and validates predictive models for breast cancer recurrence and metastasis using Recurrence-Free Survival Analysis and machine learning techniques. We merged datasets from the Molecular Taxonomy of Breast Cancer International Consortium, Memorial Sloan Kettering Cancer Center, Duke University, and the SEER program, creating a comprehensive dataset of 272, 252 rows and 23 columns.
View Article and Find Full Text PDFFactors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.
Clin Breast Cancer
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.
Background: We sought to evaluate prognostic factors in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and their relationship with short- and long-term overall survival (OS).
Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we evaluated patients with de novo HER2-positive MBC diagnosed from 2010 to 2018. Univariate analyses were performed to determine effect of each variable on OS.
Rare Presentation of Cutaneous Metastasis in Breast Carcinoma.
Cureus
December 2024
Surgery, All India Institute of Medical Sciences, New Delhi, IND.
Recurrence beyond the second year of diagnosis and metastasis to the skin and eyelids are rare occurrences in breast cancer. When cutaneous metastases present without local recurrence, they pose a significant diagnostic challenge. Here, we describe a case of breast cancer that recurred 16 years after the initial treatment, with the only indication of recurrence being unusual skin and eyelid lesions.
View Article and Find Full Text PDFCXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Breast Cancer Res
January 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Background: CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhibitors is inevitable. To address this challenge, novel strategies are required to overcome resistance, necessitating a deeper understanding of its mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!